Publikationer Magnus Essand

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer:

  1. Sarén T#, Ramachandran M#, Gammelgård G, Lövgren T, Mirabello C, Björklund ÅK, Wikström K, Hashemi J, Freyhult E, Ahlström H, Amini R-M, Hagberg H, Loskog A, Enblad G*, Essand M*. Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T-cells correlating with response in a phase II study of lymphoma patients. Clinical Cancer Research, Aug 4 (on-line): CCR-23-0178, 2023. TS and MR are shared first authors; GE and ME are shared senior authors.
  2. Sarén T, Saronio G, Marti-Torell P, Zhu X, Thelander J, Andersson Y, Hofström C, Nestor M, Dimberg A, Persson H, Ramachandran M, Yu D*, Essand M*. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nature Communications, 14:4732, 2023. DY and ME are shared senior authors.
  3. Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine J-C, Kastenmüller W, Müller AJ, Tüting T. CD4+ T-cell-induced inflammatory cell death controls immune-evasive tumours. Nature, 618:1033, 2023.
  4. Ramachandran M#, Vaccaro A#, van de Walle T#, Georganaki M, Lugano, R, Vemuri, K, Kourougkiaouri D, Vazaios K, Hedlund M, Tsaridou G, Uhrbom L, Pietilä I, Martikainen M, Van Hooren L, Olsson Bontell T, Jakola AS, Yu D, Westermark B, Essand M*, Dimberg A*. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41:1134, 2023. MR, AV and TvdW are shared first authors; ME and AD are shared senior authors.
  5. Jin C#, Ma J#, Ramachandran M, Yu D*, Essand M*. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering, 6:830, 2022. CJ and JM are shared first authors; DY and ME are shared senior authors.
  6. van Hooren L#, Vaccaro A#, Ramachandran M, Vazaios K, Libard S, van de Walle T, Georganaki M, Huang H, Pietilä I, Lau J, Ulvmar MH, Karlsson MCI, Zetterling M, Mangsbo SM, Jakola AS, Olsson Bontell T, Smits A, Essand M, Dimberg A. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. Nature Communications, 12:4127, 2021. LvH and AV are shared first authors.
  7. Martikainen M, Ramachandran M, Lugano R, Ma J, Martikainen MM, Dimberg A, Yu D, Merits A, Essand M. IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Mol Ther Oncolytics, 21:37, 2021.
  8. Ma J#, Ramachandran M, # Jin C#, Quijano-Rubio, Martikainen M, Yu D*, Essand M*. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death & Disease 11:48, 2020. JM, MR and CJ are shared first authors; ME and DY are shared senior authors of the manuscript.
  9. Ramachandran M#, Yu D#, Dyczynski M, Baskaran S, Nelander S, Zhang L, Lulla A, Lulla V, Saul S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus. Clin Cancer Research, 23:1519, 2017. MR and DY are shared first authors.
  10. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M*, Yu D*. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Molecular Medicine, 8:702, 2016. ME and DY are shared senior authors.

# delat förstaförfattarskap,  * delat sistaförfattarskap

Senast uppdaterad: 2023-08-18